Searched for
DIVIS LABS STOCKS
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Sell Divi's Laboratories, target price Rs 4,500: ICICI SecuritiesICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remai...
- Divis Labs share price 1.75 per centA total of 7,630 shares changed hands on the counter till 02:04PM (IST).
- Divis Labs shares 2.26% as Sensex risesThe stock quoted a 52-week high of Rs 6448.75 and a 52-week low of Rs 3350.05.
- Divis Labs shares 0.1% as SensexA total of 4,334 shares changed hands on the counter till 01:53PM (IST)
- Share price of Divis Labs as Sensex drops 463.32 pointsA total of 2,405 shares changed hands on the counter till 01:49PM (IST)
- Divis Labs stock price 0.24 per cent as SensexAs of 30-Sep-2024, promoters held 51.89 per cent stake in the company, while FIIs held 17.25 per cent and domestic institutional investors ...
- Divis Labs 2.38% as SensexThe stock traded at a P/E multiple of 88.36, while the price-to-book value ratio stood at 6.71.
- Divis Labs stock price 0.57 per cent as SensexAs of 30-Sep-2024, promoters held 51.89 per cent stake in the company, while FIIs held 17.25 per cent and domestic institutional investors ...
- Divis Labs stock price 2.63 per cent as SensexAs of 30-Sep-2024, promoters held 51.89 per cent stake in the company, while FIIs held 17.25 per cent and domestic institutional investors ...
- Divis Labs stock price up 0.81 per cent as Sensex slidesAs of 30-Jun-2024, promoters held 51.9 per cent stake in the company, while FIIs held 16.16 per cent and domestic institutional investors h...
- Divi's Lab down over 11% as Q3 numbers leave investors disappointedI don't track Divis fundamentally. However the chart looks like a bearish Head and Shoulder, indicating substantial more downside. Will be ...
- Divi's Labs Q3 results: Net profit tanks 65% YoY to Rs 307 cr; stock tumbles 9%Following the announcement of the results, the stock fell over 9% in intraday trade at Rs 2,969 apiece on NSE.
- Divi's Labs shares fall for 5th day, tank over 4%The company's total revenue dipped 3.6% YoY to Rs 1,935 crore for the quarter ended September 30 as against a consolidated total income of ...
- Divi's Labs Q2 Results: Profit falls 19% YoY to Rs 494 croreThe Hyderabad-based drugmaker disappointed the Street which was estimating a profit of Rs 630 crore.
- Divi's Labs Q1 Results: Profit rises 26% YoY to Rs 702 crore, beats Street estimatesTotal consolidated income for the quarter rose 17.32 per cent to Rs 2,343 crore compared with Rs 1997 crore i the corresponding quarter las...
- Divi’s Labs Q4 Results: Profit surges 78% YoY to Rs 895 crore, beats estimatesThe Board of Directors of the company has recommended a dividend of Rs 30 per share for the financial year 2021-22, subject to approval of ...
- Divi's Labs Q3 Results: Profit jumps 92% YoY to Rs 902 crore, beats estimatesRevenue from operations came in at Rs 2493.24 crore, up 46.53 per cent against Rs 1701.44 crore in the year-ago quarter.
- Divi’s Labs hits all-time high after robust Q2 resultsA recent entrant to the Nifty pack, Divi’s Labs is up 82 per cent year-to-date, and has almost doubled over the last one year.
Load More
